Kenvue Inc . (NYSE: NYSE:KVUE), known for its consumer health products, has initiated a Board of Directors succession process, which includes the appointment of Kathleen M. Pawlus and Kirk L. Perry as new independent directors.
The appointments are effective August 15 and December 1, 2024, respectively.
Pawlus, with over 40 years of experience in audit, finance, and strategy, will contribute her expertise to Kenvue's Audit Committee. Her background includes significant roles at Ernst and Young, LLP (EY), where she served as a partner and held positions such as Global Assurance Chief Financial Officer and Chief Operating Officer.
Perry, the current President and CEO of Circana, a global provider of technology, data, and predictive analytics, will join Kenvue's Compensation & Human Capital Committee. His experience spans over 30 years in consumer packaged goods and technology, having held executive positions at Procter & Gamble (NYSE:PG) and Google (NASDAQ:GOOGL).
The changes come as Kenvue enters its second year as an independent public company, aiming to bolster its governance with diverse skills and independent oversight. Larry Merlo, Chair of Kenvue's Board, expressed confidence that the new directors will be valuable assets in executing the company's growth plans and enhancing shareholder value.
In conjunction with these appointments, two Johnson & Johnson (NYSE:JNJ) executives, Peter M. Fasolo, Ph.D., and Joseph J. Wolk, will resign from the Kenvue Board in December 2024, following the sale of Johnson & Johnson's remaining stake in the company this past May. This transition is expected to result in a Board composed of 11 directors, with 10 being independent, by the 2025 Annual Meeting of Shareholders.
Kenvue, with its portfolio of well-known brands such as Aveeno®, BAND-AID® Brand, Johnson's®, Listerine®, Neutrogena®, and Tylenol®, positions itself as one of the leading firms in the consumer health space.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.